Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhode Island Diastolic Dysfunction - Heart Failure (RIDD-HF)
NCT02353312Completed
- Sponsor
- Providence VA Medical Center
- Start
- Mar 2015
- Primary completion
- Dec 2018
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of sapropterin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Providence VA Medical Center. Primary endpoint: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise at 6 months. Started Mar 2015; status: completed.
02
Drugs
sapropterin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02353312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353312.